Table 1.
Comparisons between the cases and controls.
| Cases | Controls | ORa | 95% CI | P value | |
|---|---|---|---|---|---|
| Number (%) | Number (%) | ||||
| Total | 28 | 88 | |||
| Gender | 0.96 | ||||
| Male | 17 (60.7) | 53 (60.2) | |||
| Female | 11 (39.3) | 35 (39.8) | |||
| Age (years) | |||||
| Mean ± SD | 63.43 ± 9.47 | 66.66 ± 11.64 | 0.19 | ||
| ≥60 | 17 (60.7) | 64 (72.7) | 0.23 | ||
| <60 | 11 (39.3) | 24 (27.3) | |||
| Weight (kg) | |||||
| Mean ± SD | 59.6 ± 10.9 | 58.0 ± 9.78 | 0.48 | ||
| Alcohol consumption | 3 (10.7) | 11 (12.5) | 0.80 | ||
| Smoking | 13 (46.4) | 36 (40.9) | 0.61 | ||
| Baseline Scr (mg/dL) | |||||
| Mean ± SD | 0.83 ± 0.36 | 0.91 ± 0.32 | 0.22 | ||
| Treatment regimen | |||||
| G + C/Cb | 20 (71.4) | 63 (71.6) | 0.99 | ||
| P/D + C/Cb | 8 (28.6) | 20 (22.7) | 0.52 | ||
| E + C/Cb | 3 (10.7) | 8 (9.1) | 0.73 | ||
| V + C/Cb | 10 (35.7) | 16 (18.2) | 0.05 | ||
| CCRT | 2 (7.1) | 5 (5.7) | 0.68 | ||
| Other | 3 (10.7) | 8 (9.1) | 0.73 | ||
| Number of cycles | |||||
| Mean ± SD | 4.96 ± 1.95 | 4.16 ± 1.65 | 0.034∗ | ||
| ERCC1 C118T | |||||
| CC | 14 (27.5) | 37 (72.5) | Ref | ||
| CT | 10 (18.2) | 45 (81.8) | 0.29 | 0.09~1.00 | 0.05 |
| TT | 4 (40.0) | 6 (60.0) | 0.77 | 0.15~3.93 | 0.76 |
| CT + TT | 14 (21.5) | 51 (78.5) | 0.37 | 0.12~1.14 | 0.08 |
| TP53 Arg72Pro | |||||
| Arg/Arg | 12 (38.7) | 19 (61.3) | Ref | ||
| Arg/Pro | 12 (19.4) | 50 (80.6) | 0.38 | 0.12~1.26 | 0.11 |
| Pro/Pro | 4 (17.4) | 19 (82.6) | 0.34 | 0.07~7.44 | 0.18 |
| Arg/Pro + Pro/Pro | 16 (18.8) | 69 (81.2) | 0.37 | 0.12~1.17 | 0.09 |
SD: standard deviation; Scr: serum creatinine; C: cisplatin; Cb: carboplatin; G: gemcitabine; P: paclitaxel; D: docetaxel; E: etoposide; V: vinorelbine; CCRT: combined chemoradiotherapy.
aThe odds ratio (OR) and 95% confidence interval (CI) were adjusted for age, gender, body weight, alcohol consumption, smoking, baseline Scr, treatment regimen, number of chemotherapy cycles, histology, and cancer type.
∗ P < 0.05.